ClinicalTrials.gg
CompletedNCT07275814Updated Jun 30, 2026

A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions

A Phase 3 interventional study of HRS-9231 Injection and Gadobutrol Injection in For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions, sponsored by Shanghai Shengdi Pharmaceutical Co., Ltd. Completed at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Shanghai Shengdi Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the efficacy and safety of HRS-9231 for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI); to demonstrate that, in patients requiring CNS MRI examinations, HRS-9231 is non-inferior to Gadobutrol in lesion visualization scores and show that, in patients requiring CNS MRI examinations, contrast-enhanced MRI with HRS-9231 is superior to unenhanced MRI in lesion visualization scores using the patients as their own controls; and to explore the population pharmacokinetic characteristics of HRS-9231 in CNS MRI subjects.

02

Conditions studied

  • For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions
03

In context

Lead sponsor

Shanghai Shengdi Pharmaceutical Co., Ltd is the lead sponsor of 9 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign the form, willing to cooperate with the study, and comply with trial requirements.
  2. Age ≥ 18 years, male or female.
  3. Have at least one known or highly suspected CNS enhancement abnormality or lesion detected by imaging (e.g., CT and MRI) within 12 months prior to ICF signing.

Exclusion criteria

Exclusion Criteria:

  1. Clinically unstable condition or severe diseases that may affect trial results, such as inability to ensure imaging comparability or reliability of study parameters.
  2. Severe renal impairment, defined as aGFR \< 30 mL/min/1.73 m2.
  3. Acute kidney injury, irrespective of levels.
  4. to MRI examinations or Gadobutrol, such as metallic implants ,pacemakers or claustrophobia.
  5. History of severe allergies, including drugs, contrast agents, or other allergens.
  6. Severe cardiovascular disease.
  7. Female subjects who are pregnant or breastfeeding.
  8. Other conditions deemed unsuitable by the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
250 participants (actual)

Study arms

  • Experimental
    Gadobutrol + HRS-9231 Group

    HRS-9231 enhanced MRI then Gadobutrol enhanced MRI.

    Drug: HRS-9231 Injection · Drug: Gadobutrol Injection · Device: Magnetic Resonance Imaging (MRI)

  • Experimental
    HRS-9231 + Gadobutrol Group

    Gadobutrol enhanced MRI then HRS-9231 enhanced MRI.

    Drug: HRS-9231 Injection · Drug: Gadobutrol Injection · Device: Magnetic Resonance Imaging (MRI)

Interventions

  • HRS-9231 injection.

  • DrugGadobutrol Injection

    Gadobutrol injection.

  • DeviceMagnetic Resonance Imaging (MRI)

    Magnetic Resonance Imaging (MRI).

06

What researchers measure

Primary outcomes

  1. To compare the lesion visualization scores (border delineation) of HRS-9231-enhanced with gadobutrol-enhanced MRI.

    Time frame: Day 1 after procedure.

  2. To compare the lesion visualization scores (internal morphology) of HRS-9231-enhanced with gadobutrol-enhanced MRI.

    Time frame: Day 1 after procedure.

  3. To compare the lesion visualization scores (degree of contrast enhancement) of HRS-9231-enhanced with gadobutrol-enhanced MRI.

    Time frame: Day 1 after procedure.

Secondary outcomes

  1. To compare the lesion visualization scores of HRS-9231-enhanced with unenhanced MRI.

    Time frame: Day 1 after procedure.

  2. Number, size, and location of CNS lesions in MRI images after receiving HRS-9231.

    Time frame: Day 1 after procedure.

  3. Number, size, and location of CNS lesions in MRI images after receiving gadobutrol.

    Time frame: Day 1 after procedure.

  4. HRS-9231 plasma concentration.

    Time frame: Day 1 after procedure.

  5. Population pharmacokinetic parameters - clearance.

    Time frame: Day 1 after procedure.

  6. Population pharmacokinetic parameters - apparent volume of distribution.

    Time frame: Day 1 after procedure.

  7. Overall diagnostic preference for CNS lesions on MRI images of HRS-9231 and gadobutrol.

    Time frame: Day 1 after procedure.

  8. Diagnostic confidence of MRI images of HRS-9231 and gadobutrol.

    Time frame: Day 1 after procedure.

  9. Technical adequacy of MRI images of HRS-9231 and gadobutrol.

    Time frame: Day 1 after procedure.

07

Study locations

2 sites
  • Peking University People's Hospital
    Beijing, Beijing Municipality 100044, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 450003, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2025 to primary completion in Jun 2026, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Dec 10, 2025
StartActual
Nov 17, 2025
Primary completionActual
Jun 17, 2026
CompletionActual
Jun 17, 2026
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07275814
Responsible party
Sponsor
First posted
Dec 10, 2025
Start date
Nov 17, 2025
Primary completion
Jun 17, 2026
Completion
Jun 17, 2026
Last update
Jun 30, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-9231

Start the discussion